Houlihan Financial Resource Group’s Ionis Pharmaceuticals IONS Stock Holding History

Houlihan Financial Resource Group’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	$58K	Buy	+1,170	New	+$65K	0.03%	162

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Houlihan Financial Resource Group's IONS Position: Q3 2020 in Review

Houlihan Financial Resource Group opened a new position in Ionis Pharmaceuticals (IONS) in Q3 2020: 1,170 shares worth $58K. The stake represents 0.03% of the portfolio and ranks #162 among its holdings.

367 funds tracked by Wall St. Rank hold IONS as of Q3 2020.

Houlihan Financial Resource Group held 1,170 shares of Ionis Pharmaceuticals worth $58K as of Q3 2020.
Ionis Pharmaceuticals was a new Houlihan Financial Resource Group position in Q3 2020.
Ionis Pharmaceuticals made up 0.03% of Houlihan Financial Resource Group's portfolio in Q3 2020, its #162 holding.
367 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q3 2020.

Based on Houlihan Financial Resource Group's 13F filing for Q3 2020, filed 13 Nov 2020.